Lung Cancer
Feature
Not all lung cancer patients receive treatment
Reasons include metastasis and refusal, and rates by state vary from 8% to 30%, the American Lung Association reports.
Conference Coverage
Neoantigen vaccine appears safe and active in NSCLC
NATIONAL HARBOR, MD. – The vaccine produced only grade 1 adverse events and yielded responses in 7 of 24 patients,...
From the Journals
Lorlatinib induces deep responses in ROS1-positive NSCLC
Among 40 crizotinib-pretreated patients, 14 patients (35%) had an objective response on lorlatinib, with a median duration of response of 13.8...
Opinion
‘You had me at hello’: ESMO studies confirm survival benefits in NSCLC and breast cancer
Dr. Alan P. Lyss reflects on the significance of two studies from ESMO 2019 that show significant survival improvements in NSCLC and breast cancer...
Conference Coverage
Atezolizumab bests chemo in NSCLC patients with high PD-L1 expression
Atezolizumab provided a 7-month benefit in median overall survival for patients with stage IV non–small cell lung cancer and high PD-L1 expression...
News from the FDA/CDC
Lung cancer on the decline, but still higher among men than women
CDC stresses universal screening for smoking and other lung cancer risk factors.
Conference Coverage
Nivolumab benefit for NSCLC persists at 5-year follow-up
BARCELONA – Nivolumab, compared with docetaxel chemotherapy, led to a fivefold improvement in 5-year overall...
Conference Coverage
Fluoroscopic system can improve targeting of lung lesions
The system increased the percentage of cases in which the target overlapped with the lesion.
Latest News
Levothyroxine dose for checkpoint inhibitor toxicity may be too high
CHICAGO – Dosing need not be automatically boosted when starting checkpoint inhibitor therapy.
Conference Coverage
Immune checkpoint inhibition in SCLC: Modest outcomes, many questions
Immune checkpoint inhibitors have activity in SCLC, but achieving more durable disease control and better survival requires greater understanding...
Conference Coverage
Patients have good recall on lung cancer screening scan benefits, not risks
NEW ORLEANS – Results suggest need for ongoing patient education beyond the initial shared decision-making encounter.